Advertisement
NVS vs PFE
Which Stock Would AI Choose? Novartis AG (NVS) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: Between NVS and PFE, Tickeron's AI currently favors Novartis (NVS) on the basis of stronger trend consistency and more visible growth catalysts.
- Novartis has posted stronger relative performance over the past year, supported by momentum in growth medicines such as Kisqali, Kesimpta, Pluvicto, and Scemblix.
- Pfizer offers a substantially higher dividend yield, but its shares remain pressured by declining COVID-19 product revenue and an approaching patent cliff on key franchises.
- Novartis is expanding margins and raising profit guidance, while Pfizer is managing a revenue transition through cost discipline and acquisitions such as its oncology and obesity-related moves.
- Risk profiles differ meaningfully: Novartis faces generic erosion on older brands, while Pfizer faces a larger, multi-year loss-of-exclusivity burden across several blockbusters.
- For deeper context, explore NVS Major News and NVS Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- To see which strategies AI is deploying across the market right now, visit the curated Trending AI Robots page.
Introduction
Novartis AG (NVS) and Pfizer Inc. (PFE) are two of the largest global pharmaceutical companies, yet they sit at very different points in their business cycles. This stock comparison is relevant for investors weighing growth momentum against income and value. Novartis has been executing a focused, post-spinoff strategy built around innovative medicines, while Pfizer is working through a post-pandemic reset in which declining COVID-19 product sales are being offset by cost reductions and a diversified pipeline. Traders and long-term investors alike may find the contrast instructive, particularly when assessing relative performance, market positioning, and how AI-driven analysis interprets the two names under current conditions.
NVS Overview and Recent Performance
Novartis AG (NVS) is a Swiss pharmaceutical company focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. In recent quarters, the company has delivered high single-digit sales growth and expanding core margins, reaching its long-term margin target ahead of schedule. Growth has been driven by newer priority brands, including Kisqali (breast cancer), Kesimpta (multiple sclerosis), Pluvicto (prostate cancer), Scemblix (leukemia), and Leqvio (cholesterol). Over the past year, the stock has meaningfully outperformed, with recent market activity reflecting steady upward trend and trading above key moving averages. Sentiment has been supported by consistent earnings beats and margin expansion, although generic competition in the United States on older brands such as Entresto, Promacta, and Tasigna has created a partial offset. Overall, investors have responded favorably to Novartis's focus and pipeline execution.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a U.S.-based pharmaceutical giant with a broad portfolio spanning primary care, specialty care, and oncology. The company's recent performance has been shaped by a sharp normalization in COVID-19-related revenue, with sales of the antiviral Paxlovid and the Comirnaty vaccine falling well below pandemic-era peaks. In response, Pfizer has leaned on cost-cutting initiatives, an emphasis on oncology following its Seagen acquisition, and strategic moves toward the obesity market, including a contested bid for Metsera. Non-COVID product revenue has grown modestly, but the top line has remained under pressure overall. The shares have traded in a relatively narrow, sideways-to-lower range in recent periods and have underperformed the broader market over the past year. A notably high dividend yield has attracted income-oriented investors, though growth concerns and an approaching patent cliff on products including Eliquis, Vyndaqel, and Ibrance continue to weigh on sentiment.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots drawn from a larger pool of hundreds of automated strategies that trade thousands of different tickers. Because not every bot suits every market regime, only those demonstrating the strongest recent alignment with current conditions are featured in this section. These bots vary widely in trading style, strategy, timeframe, risk profile, performance statistics, and the sets of tickers they follow, allowing users to evaluate approaches ranging from short-term momentum to longer-horizon trend following. Whether you are comparing names like NVS and PFE or scanning the broader market, exploring the Trending AI Robots page can help you identify the strategies currently performing best.
Head-to-Head Comparison
Novartis and Pfizer diverge on several dimensions. In terms of business model, Novartis is a leaner, more innovation-focused organization following its Sandoz spinoff, while Pfizer remains a diversified conglomerate with a heavier reliance on scale and established franchises. Growth drivers also differ: Novartis's catalysts come from accelerating sales of recently launched oncology and neuroscience products, whereas Pfizer's growth leans on oncology buildout and a prospective obesity entry that is not yet resolved. On momentum, Novartis has shown greater relative strength, while Pfizer has been more range-bound. Risk profiles contrast as well—Novartis faces near-term generic erosion concentrated in a few legacy brands, while Pfizer confronts a broader, multi-year loss-of-exclusivity wave. Finally, market sentiment has been more constructive toward Novartis's consistent execution, whereas Pfizer's higher dividend yield and lower valuation reflect investor uncertainty about future revenue stability.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative performance, margin expansion, and the clarity of near-term catalysts, Tickeron's AI would likely favor NVS over PFE in the current environment. Novartis's steadier price trend, stronger recent returns, and visible growth from its priority brands contrast with Pfizer's still-unresolved revenue transition and patent-cliff exposure. That said, the verdict is probabilistic rather than absolute: Pfizer's high yield and low valuation could appeal under different market conditions, and any shift in its pipeline or obesity-related catalysts could narrow the gap. As always, the balance of trend, stability, and momentum currently points toward Novartis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Buy and PFE is a Hold.
NVS in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.421). P/E Ratio (24.370) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
PFE sees MACD Histogram just turned negative
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 30 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 195 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
NVS | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 33 | 83 | |
PRICE GROWTH RATING 1..100 | 40 | 27 | |
P/E GROWTH RATING 1..100 | 12 | 4 | |
SEASONALITY SCORE 1..100 | n/a | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (96). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.
NVS's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that NVS’s stock grew significantly faster than PFE’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as NVS (40). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
PFE's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as NVS (12). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
| NVS | PFE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 54% | 4 days ago 54% |
| Stochastic ODDS (%) | 4 days ago 38% | 4 days ago 55% |
| Momentum ODDS (%) | 4 days ago 54% | 4 days ago 53% |
| MACD ODDS (%) | N/A | 4 days ago 67% |
| TrendWeek ODDS (%) | 4 days ago 56% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 51% | 4 days ago 48% |
| Advances ODDS (%) | 14 days ago 55% | 8 days ago 54% |
| Declines ODDS (%) | N/A | 4 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 30% | N/A |
| Aroon ODDS (%) | 4 days ago 51% | 4 days ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 3 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- NVS’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- NVS’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 2 bullish, 5 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а +1.09% price change this week, while PFE (@Pharmaceuticals: Major) price change was -2.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.88%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +5.50%.
Reported Earning Dates
NVS is expected to report earnings on Feb 03, 2027.
PFE is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.88% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.20% | ||
| BMY - PFE | 60% Loosely correlated | -1.57% | ||
| AMGN - PFE | 53% Loosely correlated | +0.03% | ||
| GSK - PFE | 51% Loosely correlated | -0.16% | ||
| NVS - PFE | 50% Loosely correlated | +0.38% | ||
| BIIB - PFE | 46% Loosely correlated | +1.81% | ||
More | ||||